Geographic Atrophy Clinical Trial
— GAINOfficial title:
Characterization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration
Verified date | March 2015 |
Source | Institut de la Macula y la Retina |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ethics Committee |
Study type | Observational |
Age-related macular degeneration is one of the leading causes of blindness worldwide. The factors that induce the progression of geographic atrophy, the advanced form of dry age-related macular degeneration, remain poorly understood. The aims of this study are to describe the natural history of geographic atrophy and identify potential risk factors associated with a faster spread of atrophy that may be used to develop rational therapies.
Status | Completed |
Enrollment | 96 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 50 Years and older |
Eligibility |
Inclusion Criteria: - Both sexes - 50 years of age or older - Uni or bilateral areas of geographic atrophy in the macula (as defined as areas devoid of retinal pigment epithelium measuring at least 0.5 disk areas on a 35º fundus photograph centered on field 2) secondary to age-related macular degeneration - Willing to provide Informed consent Exclusion Criteria: - Other causes of geographic atrophy aside from age-related macular degeneration (ie, drug induced, central serous chorioretinopathy) - Prior history of wet age-related macular degeneration - Other significant concomitant macular diseases (ie, significant epiretinal membrane, stage II-IV macular hole) - Previous treatment with macular laser photocoagulation, photodynamic therapy, antiangiogenic drugs or other treatments for wet age-related macular degeneration - Intraocular surgery aside from phacoemulsification - Inability to measure the full extent of the area of atrophy on a 35º fundus autofluorescence image centered on field 2 - Areas of geographic atrophy in direct contact with peripapillary areas of atrophy |
Observational Model: Case-Only, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Spain | Institut de la màcula i de la retina | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Institut de la Macula y la Retina |
Spain,
Biarnés M, Forero CG, Arias L, Alonso J, Monés J. Reappraisal of geographic atrophy patterns seen on fundus autofluorescence using a latent class analysis approach. Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):8302-8. doi: 10.1167/iovs.13-13542. — View Citation
Biarnés M, Monés J, Trindade F, Alonso J, Arias L. Intra and interobserver agreement in the classification of fundus autofluorescence patterns in geographic atrophy secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012 Apr; — View Citation
Monés J, Biarnés M, Trindade F, Arias L, Alonso J. Optical coherence tomography assessment of apparent foveal swelling in patients with foveal sparing secondary to geographic atrophy. Ophthalmology. 2013 Apr;120(4):829-36. doi: 10.1016/j.ophtha.2012.09.05 — View Citation
Monés J, Biarnés M, Trindade F. Hyporeflective wedge-shaped band in geographic atrophy secondary to age-related macular degeneration: an underreported finding. Ophthalmology. 2012 Jul;119(7):1412-9. doi: 10.1016/j.ophtha.2012.01.026. Epub 2012 Mar 21. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Median/mean change in best-corrected visual acuity as measured with an Early Treatment Diabetic Retinopathy Study chart | From baseline to last follow-up | No | |
Other | Percentage of eyes developing new choroidal neovascularization in the study eye as evaluated with fluorescein angiography and spectral-domain optical coherence tomography | From baseline to last follow-up | No | |
Other | Median/mean change in area of geographic atrophy as measured in mm2 with fundus autofluorescence on a 30º image centered on field 2 | Principal component analysis will be used to reduce the number of independent variables to increase, if possible, the power of the study to detect an association | From baseline to last follow-up | No |
Primary | Median/mean change in area of geographic atrophy as measured in mm2 with fundus autofluorescence on a 30º image centered on field 2 | For measures related to change in the area of atrophy, a multivariable model will be fit and will include as an independent variable (amongst other presumed risk factors) fundus autofluorescence patterns | From baseline to last follow-up | No |
Secondary | Median change in area of geographic atrophy as measured in square root of mm2 with fundus autofluorescence on a 30º image centered on field 2 | Exploratory analysis, either in the main publication or in another paper | From baseline to last follow-up | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06161584 -
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
||
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Completed |
NCT02515942 -
CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)
|
Phase 2 | |
Completed |
NCT02503332 -
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
|
Phase 2 | |
Recruiting |
NCT04339764 -
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT03295877 -
Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
|
Phase 1 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00973011 -
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
|
Phase 1 | |
Terminated |
NCT02247479 -
A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT06006585 -
A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
|
Phase 1 | |
Recruiting |
NCT05961332 -
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy
|
N/A | |
Terminated |
NCT02247531 -
A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT02332343 -
Sparing of the Fovea in Geographic Atrophy Progression
|
N/A | |
Completed |
NCT01002950 -
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy
|
Phase 2 | |
Completed |
NCT03777332 -
Study to Evaluate the Safety of Intravitreal APL-2 in Patients Diagnosed With Geographic Atrophy
|
Phase 1 | |
Active, not recruiting |
NCT04676854 -
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
|
N/A | |
Recruiting |
NCT02372916 -
Geographic Atrophy and Intravitreal Ranibizumab Injections
|
N/A | |
Active, not recruiting |
NCT05380492 -
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Terminated |
NCT04607148 -
A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
|
Phase 2 | |
Terminated |
NCT02087085 -
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration
|
Phase 2 |